Monthly Newsletter

By allowing Carterra’s superior epitope, binding affinity, and kinetic information to occupy the same view as sequence information, the IGX Platform enables faster, better decision-making in therapeutic discovery.

Carterra Inc., the world leader in label-free high-throughput antibody discovery and development, and ENPICOM B.V., an innovative bioinformatics software solutions provider, announced today a collaboration to streamline the analysis of rapidly growing sequencing and antibody screening data generated in the lab. The collaboration will focus on accelerating the identification of clinical-grade antibody candidates with improved characteristics.

Carterra’s high-throughput Surface Plasmon Resonance (HT-SPR) biosensor technology enables detailed screening and characterization of thousands of antibodies in one step, allowing up to 100 times the throughput of traditional platforms in 10% of the time while using only 1% of the sample required by other systems. The Carterra LSA and LSAXT have unparalleled screening capabilities which have made them an essential technology for pharmaceutical companies, biotechs, CROs, government agencies, and academia. Among its accomplishments, the LSA was instrumental in the 90-day discovery and development of the world’s first COVID-19 therapeutic, bamlanivimab, by Eli Lilly and AbCellera.

ENPICOM’s IGX Platform helps researchers manage, analyze, and visualize immune repertoire data. The platform excels at integrating different sequencing datasets and incorporating experimental data and metadata. The rapid uptake of high-throughput repertoire sequencing (Rep-Seq) in antibody discovery campaigns in recent years provides dramatically more viable therapeutic candidates to explore, moving from a library of hundreds to millions. This increased sampling space enables scientists to find clinical candidates with more diverse binding kinetics, affinity, and developability characteristics.

"Combining the high-quality binding data on thousands of antibodies screened by the Carterra platforms with the vast number of sequences that are obtained with Rep-Seq allows our clients to map the candidate space to an unprecedented level," said Paul van der Velde, CEO at ENPICOM. "By leveraging the best of both technologies, we enable researchers to extrapolate the binding characteristics to a much larger pool of candidates to find even better lead molecules."

The combined analysis of the high-quality datasets generated using Carterra’s label-free platforms and large sequencing data requires innovative and flexible software tools, which ENPICOM’s IGX Platform provides. Moreover, due to its scalable computational infrastructure, the IGX Platform creates a unique environment to leverage these datasets to train and develop AI and ML models in therapeutic discovery.

"We’re excited to join ENPICOM in enabling antibody discovery labs utilizing NGS and AI/ML routines with industry-leading epitope and kinetic analysis data as they interrogate large candidate libraries," said Chris Silva, Vice President of Marketing and Product at Carterra. "These solutions will benefit investigators around the world by allowing them to create new and revolutionary therapeutics rapidly."

About ENPICOM

ENPICOM is an innovative bioinformatics software engineering company delivering ground-breaking products and customized solutions to decode the immune system and improve human health. With a diverse team of experts in various disciplines, ENPICOM serves customers from all over the world, ranging from academic research centers doing basic research related to the immune system to biotech and global pharmaceutical companies focusing on the discovery and development of novel antibodies and vaccines.

Leveraging a unique mix of immunology knowledge, bioinformatics methods, and software development skills, ENPICOM offers a world-class repertoire sequencing data analysis solution – the ImmunoGenomiX (IGX) Platform. IGX is an innovative platform to manage, analyze, visualize, and interpret immune repertoire sequencing data from T and B cell receptors. Moreover, together with its partners, ENPICOM also delivers full immune repertoire sequencing and analysis on demand.

About Carterra, Inc.

Carterra® is privately held and is the leading provider of high-throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s LSA® instrument, software, and consumables for biotherapeutic discovery and characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high-throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. The new LSAXT provides enhanced optics to enable additional applications in biotherapeutic discovery and characterization. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity (previously PerkinElmer).